Promising GVHD prevention trial halted early – too few patients to draw conclusions

NCT ID NCT06271616

Terminated Disease control Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase II trial tested whether the drug ibrutinib could prevent chronic graft-versus-host disease (GVHD) in adults who had received a donor stem cell transplant. Only 2 people enrolled before the study was terminated early. Because of the very small number of participants, no reliable conclusions can be drawn about whether ibrutinib helps prevent GVHD.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ibrutinib
What this could lead to: If this approach had worked, it could have pointed toward a way to prevent chronic GVHD after stem cell transplants.
What could go wrong: The trial was terminated early with only 2 participants, so we have very little data. It is unclear if ibrutinib is effective or safe for this use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC GRAFT VERSUS HOST DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Bronchiolitis Obliterans Syndrome hematopoietic and lymphoid system neoplasm chronic graft versus host disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC GRAFT VERSUS HOST DISEASE HEMATOPOIETIC AND LYMPHATIC SYSTEM NEOPLASM

Contacts and locations

Locations

Mayo Clinic in Florida

Jacksonville, Florida, 32224-9980, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.